UBS AG has given Roche shares a "Neutral" rating and set a target price of 270 francs.
Analyst Matthew Weston observed that Roche's performance in the third quarter slightly exceeded expectations, with growth drivers remaining on track.
As of 12:04 p.m., Roche shares were trading at CHF 271.60, down 0.2 percent, reflecting a decline of 0.59 percent from the fixed price mark.
The stock has seen a year-to-date increase of 15.7 percent.
The financial results for Q4 2024 are scheduled for release on January 30, 2025.